TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05451771
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
Study: NCT05451771
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
Study: NCT05451771
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
Study: NCT05451771
Drug: Venetoclax MTD with Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
Study: NCT05771181
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
Study: NCT05771181
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
Study: NCT05771181
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
Study: NCT06207539
Drug: misoprostol under the generic name of misotac tablets
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.
Study: NCT04995016
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 inhibitor，Pembrolizumab 200mg IV, every 3 weeks.
Study: NCT04995016
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor，licensed for use in treatment of renal cell carcinoma. Oral treatment Axitinib given 5 mg PO BID.
Study: NCT05724849
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm/group description.
Study: NCT06482008
Drug: Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib
Normalized name: Sus scrofa artery preparation
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC every 3 weeks until 6 treatments have been completed, or HAIC therapy is terminated if patients have not reached 6 treatments and experience intolerable adverse effects; adebrelimab, fixed dose 1200 mg, IV, D1, every 21 days (Q3W), in combination with apatinib, 250 mg (0.25 g), orally, once daily (QD), consecutively dosing in 3-week (21-day) treatment cycles. Study treatment will continue until the subject develops an intolerable toxic reaction, withdraws informed consent, and progresses according to RECIST v1.1 as confirmed by the investigator (after the subject develops disease progression as defined by RECIST v1.1, if the investigator assesses that the subject is still clinically beneficial and can tolerate the study treatment, the subject may continue to receive the study drug; if it is considered that the subject no longer has clinical benefit, then treatment may be terminated), or other termination criteria specified in the protocol, whichever occurs first.
Study: NCT04552691
Drug: Pegunigalsidase Alfa
Normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegunigalsidase alfa is a recombinant ERT (enzyme replacement therapy) used to treat Fabry disease (dosage: 1 mg/kg body weight every 2 weeks).
Study: NCT05296603
Drug: IBI-322 Plus Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IBI322 is based on the 3+3 model, with a dose ascent starting from 10mg
Study: NCT05188859
Drug: Sintilimab+Anlotinib+Pemetrexed+Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sintilimab 200mg+Anlotinib 12mg+Pemetrexed 500mg/m²+Cisplatin 75mg/m2
Study: NCT06112041
Drug: ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin
Study: NCT05410626
Drug: prolong-release methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
Study: NCT05338190
Drug: Combination of Rituximab with subcutaneous belimumab
Normalized name: Belimumab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
Study: NCT05338190
Drug: Combination of Rituximab with subcutaneous placebo
Normalized name: combinations of barbiturates
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
Study: NCT04585958
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00231348
Drug: Nefazodone
Normalized name: Nefazodone
DrugBank: Nefazodone (DB01149)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06267963
Drug: Oral PF-07220060
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.
Study: NCT05464654
Drug: 3 g Polynucleotide vaginal suppositories
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g polynucleotide vaginal suppositories were administered nightly for 6 days.
Study: NCT05464654
Drug: Conjugated estrogens cream 1g Tube
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
Study: NCT04753164
Drug: ACT-539313
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Study: NCT06319599
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.
Study: NCT06476223
Drug: Artificial saliva containing cumin and ginger extract
Normalized name: cumin allergenic extract
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The sample will be sprayed 2 puff/time, 3 times/day, for 14 days.
Study: NCT05316662
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study: NCT06484153
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two doses of pirfenidone (200 mg,tid,po;500 mg,tid,po) were set up. Using the 3+3 design, the DLT observation period is 28 days.
Study: NCT06484153
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg, orally, qd
Study: NCT06484153
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg iv every 3 weeks
Study: NCT05442515
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose).
Study: NCT04655716
Drug: Sodium Bicarbonate 150Meq/L/D5W Inj
Normalized name: SODIUM BICARBONATE 150MEQ/L/D5W INJ
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urine alkalinisation will be performed to achieve urine pH 7.5-8.5. Urine alkalinisation will be continued for up to 10 days or until patient is discharged or until primary endpoint is reached. Urine pH will be measured at point of care by dipstick.
Study: NCT05826964
Drug: PI3K inhibitor + SERD
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive standard of care one PI3K inhibitor therapy (Alpelisib), in combination with SERD therapy (Fulvestrant) in Step 2 Arm 2 and Step 3. PI3K inhibitor + SERD therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT05826964
Drug: PI3K inhibitor + AI
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive standard of care a PI3K inhibitor therapy (Alpelisib), in combination with an AI therapy (Letrozole) in Step 2 Arm 2 and Step 3. PI3K inhibitor + AI therapy administered as one of the available options for early switch from SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT06225089
Drug: pericapsuler nerve block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
Study: NCT06502288
Drug: 625 mg of amoxicillin with combined clavulanic acid tablet
Normalized name: amoxicillin / clavulanate
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group must take 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction.
Study: NCT05935579
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg will be administered intravenously once every three weeks, with intravenous infusion on Day 1 of each cycle.
Study: NCT05935579
Drug: Lenvatinib Oral Product
Normalized name: lenvatinib Oral Product
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of lenvatinib is 12mg/day for patients with a body weight of ≥60 kg, and 8mg/day for patients with a body weight of \<60 kg, taken once daily.
Study: NCT05439356
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
Study: NCT05439356
Drug: Placebo colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
Study: NCT06218004
Drug: Envafolimab combined with chemotherapy
Normalized name: miconazole
DrugBank: Envafolimab (DB15769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: envafolimab: 150 mg once every 1 week for 8 doses subcutaneously on day 1 Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.
Study: NCT04888546
Drug: Anlotinib hydrochloride capsules＋ TQB2450 injection
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.
Study: NCT06367465
Drug: Glecaprevir-pibrentasvir
Normalized name: glecaprevir-pibrentasvir
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
Study: NCT06237153
Drug: Triamcinolone Acetonide extended release suspension
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active steroid
Study: NCT05804383
Drug: BMS-984923
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules
Study: NCT05651464
Drug: Vancomycine
Normalized name: Vancomycine
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of 15-20 mg per kgKG Vancomycine I.V. prior to ECMO liberation
Study: NCT05179421
Drug: Low dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 minute IV infusion of saline followed by a 10 minute infusion of oxytocin 1.3 micrograms
Study: NCT05179421
Drug: High dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 minute IV infusion of oxytocin 0.3 micrograms followed by a 10 minute infusion of oxytocin 7 micrograms
Study: NCT04966676
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antineoplastic agent
Study: NCT04966676
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antineoplastic agent
Study: NCT05312671
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
Study: NCT05312671
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
Study: NCT05312671
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
Study: NCT05312671
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
Study: NCT03594162
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
Study: NCT05871073
Drug: Ropivacaine 0.75% Injectable Solution
Normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WOUND INFILTRATION AFTER SPINAL SURGERY
Study: NCT05871073
Drug: dexamethasone 8mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WOUND INFILTRATION AFTER SPINAL SURGERY
Study: NCT05180461
Drug: emodepside
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: emodepside tablet
Study: NCT05180461
Drug: matching placebo of emodepside
Normalized name: Emodepside
DrugBank: Emodepside (DB11403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: emodepside matching placebo tablet
Study: NCT05180461
Drug: ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ivermectin tablet (overencapsulated for blinding)
Study: NCT05180461
Drug: matching placebo of ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: matching placebo of overencapsulated ivermectin tablet
Study: NCT06062966
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100 mg SC daily will be administered to sujects on chronic inotrope treatment who are not candidates for transplantation or left ventricular assist device (LVAD).
Study: NCT05853744
Drug: lavender essential oil inhaled using cotton balls
Normalized name: Lavender oil
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
Study: NCT05409235
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive vehicle control
Study: NCT05853744
Drug: lavender essential oil inhaled using face mask
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.
Study: NCT04741165
Drug: HX008
Normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT04741165
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT04741165
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally once a day during each 21-day cycle
Study: NCT04709575
Drug: REGN5713
Normalized name: Immunoglobulin G4 [224-proline], anti-(Betula alleghaniensis allergen Bet v 1) (human monoclonal REGN5713 γ4-chain), disulfide with human monoclonal REGN5713 κ-chain, dimer
DrugBank: Bremzalerbart (DB19417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT05224492
Drug: Sulforaphane
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of Sulforaphane powder once daily.
Study: NCT05049161
Drug: Temelimab 18 mg/kg
DrugBank: Temelimab (DB15634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
Study: NCT05049161
Drug: Temelimab 36mg/kg
DrugBank: Temelimab (DB15634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
Study: NCT05049161
Drug: Temelimab 54 mg/kg
DrugBank: Temelimab (DB15634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total)
Study: NCT05853744
Drug: Distilled water
Normalized name: Distilled Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
Study: NCT05466019
Drug: Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ, Q2W Toripalimab 3mg/kg, intravenously administered on the first day of each cycle, Q2W.